“…Bacterial resistance to quinolones or fluoroquinolones is usually accomplished by interference with bacterial DNA metabolism mediated by mutations in bacterial DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC and parE) genes, as well as by active efflux (Eaves et al, 2004;Griggs, Gensberg, & Piddock, 1996;Piddock, 2002;Piddock, Ricci, McLaren, & Griggs, 1998). These mutations prevent antimicrobial agents from binding to their topoisomerase targets and carrying out their antimicrobial activity (Heisig, 1993).…”